Ricky W. Johnstone

Active 1948–2025

144
Papers
34,494
Citations
97
h-index
144
i10-index

Citations

Citations per year for Ricky W. Johnstone1959: 1 citations1978: 1 citations1991: 1 citations1992: 4 citations1994: 2 citations1995: 4 citations1996: 5 citations1997: 6 citations1998: 20 citations1999: 32 citations2000: 50 citations2001: 62 citations2002: 98 citations2003: 200 citations2004: 219 citations2005: 218 citations2006: 192 citations2007: 279 citations2008: 271 citations2009: 345 citations2010: 342 citations2011: 328 citations2012: 312 citations2013: 356 citations2014: 354 citations2015: 456 citations2016: 401 citations2017: 417 citations2018: 396 citations2019: 1,227 citations2020: 1,298 citations2021: 1,300 citations2022: 1,039 citations2023: 755 citations2024: 1,139 citations2025: 566 citations2026: 10 citations1960–1977: no citations, so these years are not shown1979–1990: no citations, so these years are not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,398 citing papers, 27.8% of this breakdownChina: 2,371 citing papers, 15% of this breakdownGermany: 891 citing papers, 5.6% of this breakdownAustralia: 864 citing papers, 5.5% of this breakdownUnited Kingdom: 828 citing papers, 5.2% of this breakdownItaly: 606 citing papers, 3.8% of this breakdownFrance: 493 citing papers, 3.1% of this breakdownCanada: 480 citing papers, 3% of this breakdownJapan: 366 citing papers, 2.3% of this breakdownIndia: 340 citing papers, 2.2% of this breakdownSpain: 324 citing papers, 2.1% of this breakdownNetherlands: 292 citing papers, 1.9% of this breakdown
0%27.8%Other 22.5%

Fields

  • Biochemistry, Genetics and Molecular Biology54.3%
  • Medicine30.6%
  • Immunology and Microbiology10.1%
  • Neuroscience0.9%
  • Engineering0.8%
  • Chemistry0.7%
  • Other2.6%

Topics

  • Histone Deacetylase Inhibitors Research7.6%
  • Protein Degradation and Inhibitors5.1%
  • Epigenetics and DNA Methylation4.1%
  • Cell death mechanisms and regulation2.8%
  • Immune Cell Function and Interaction2.6%
  • Ubiquitin and proteasome pathways2.2%
  • Other75.6%

Coauthors

All papers

Open in search
  1. Targeting the epigenetic regulation of antitumour immunity

    Authors: , , , - Nature Reviews Drug Discovery 2020 cited by 620

  2. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

    Authors: , - Nature Reviews Drug Discovery 2014 cited by 1,525

  3. Tumor immune evasion arises through loss of TNF sensitivity

    Authors: , , , , , , , , , , , , , , , , , - Science Immunology 2018 cited by 393

  4. New and emerging HDAC inhibitors for cancer treatment

    Authors: , - Journal of Clinical Investigation 2014 cited by 1,377

  5. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pat Pilling, Meghan Hattarki, Olan Dolezal, Matthew L. Dennis, Hendrik Falk, Bin Ren, Susan A. Charman, Karen L. White, Jai Rautela, Andrea Newbold, Edwin D. Hawkins, Ricky W. Johnstone, Nicholas D. Huntington, Thomas S. Peat, Joan K. Heath, Andreas Strasser, Michael W. Parker, Gordon K. Smyth, Ian P. Street, Brendon J. Monahan, Anne K. Voss, Tim Thomas - Nature 2018 cited by 314

  6. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Edwin Clark, David M. Wilson, Stephen E. Fawell, Alexander W. Hird - Nature Communications 2018 cited by 486

  7. Anticancer activities of histone deacetylase inhibitors

    Authors: , , - Nature Reviews Drug Discovery 2006 cited by 2,917

  8. Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor

    Authors: , , , , , , , , , , , , , , - Immunity 2012 cited by 560

  9. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nathanael S. Gray, Alessandro Gardini, Ricky W. Johnstone - Cell 2021 cited by 227

  10. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

    Authors: , , , , , , , , , , , , , , , , , - Cell Reports 2017 cited by 300

  11. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Phillippa C. Taberlay, Kenneth D. Bromberg, Albert Lai, Anthony T. Papenfuss, Gordon K. Smyth, Rhys S. Allan, Jonathan D. Licht, Dan A. Landau, Omar Abdel‐Wahab, Jake Shortt, Stephin J. Vervoort, Ricky W. Johnstone - Molecular Cell 2021 cited by 170

  12. Targeting transcription cycles in cancer

    Authors: , , , , , - Nature reviews. Cancer 2021 cited by 168

  13. IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2020 cited by 107

  14. BET inhibitor resistance emerges from leukaemia stem cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2015 cited by 548

  15. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2017 cited by 321

  16. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion

    Authors: , , , , , , , , - Cell Reports 2019 cited by 144

  17. Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling

    Authors: , , , , - Immunity 2012 cited by 457

  18. Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2012 cited by 560

  19. Apoptosis

    Authors: , , - Cell 2002 cited by 2,243

  20. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity

    Authors: , , , , , , , , , , , , , , , , , , , , - Science Advances 2020 cited by 165

  21. Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - PLoS Pathogens 2014 cited by 511

  22. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 129

  23. Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies

    Authors: , , , , , , , , , - The Journal of Immunology 2020 cited by 91

  24. Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 59